Agnieszka Kula
Overview
Explore the profile of Agnieszka Kula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ochman B, Kot A, Mielcarska S, Kula A, Dawidowicz M, Koszewska D, et al.
Curr Issues Mol Biol
. 2024 Dec;
46(12):13617-13646.
PMID: 39727942
SIGLEC9 (sialic acid-binding Ig-like lectin 9) is a molecule thought to have a significant influence on the immune properties of the colorectal cancer (CRC) tumor microenvironment (TME). In our study,...
2.
Ochman B, Limanowka P, Mielcarska S, Kula A, Dawidowicz M, Wagner W, et al.
Curr Issues Mol Biol
. 2024 Sep;
46(9):10218-10248.
PMID: 39329961
Semaphorins (SEMAs), ADAM, and ADAMTS family members are implicated in various cancer progression events within the tumor microenvironment across different cancers. In this study, we aimed to evaluate the expression...
3.
Strzalkowska B, Strzelczyk J, Dawidowicz M, Kula A, Mielcarska S, Szarek R, et al.
Clin Neurol Neurosurg
. 2024 Aug;
245:108519.
PMID: 39216416
Hashimoto's thyroiditis (HT) is an autoimmune disorder characterized by the destruction of thyroid follicular cells by thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb), leading to hypothyroidism. Hashimoto's encephalopathy (HE)...
4.
Dawidowicz M, Kot A, Mielcarska S, Psykala K, Kula A, Waniczek D, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061159
Anti-cancer immunotherapies entirely changed the therapeutic approach to oncological patients. However, despite the undeniable success of anti-PD-1, PD-L1, and CTLA-4 antibody treatments, their effectiveness is limited either by certain types...
5.
Kula A, Koszewska D, Kot A, Dawidowicz M, Mielcarska S, Waniczek D, et al.
Cells
. 2024 May;
13(10.
PMID: 38786018
Cancer immunotherapy is a rapidly developing field of medicine that aims to use the host's immune mechanisms to inhibit and eliminate cancer cells. Antibodies targeting CTLA-4, PD-1, and its ligand...
6.
Dawidowicz M, Kula A, Mielcarska S, Swietochowska E, Waniczek D
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38732263
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the...
7.
Kula A, Dawidowicz M, Mielcarska S, Swietochowska E, Waniczek D
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731979
HHLA2 is a checkpoint from the B7 family that can play a co-stimulatory or co-inhibitory role in cancer, depending on the binding receptor. The aim of this meta-analysis was to...
8.
Mielcarska S, Dawidowicz M, Kula A, Kiczmer P, Skiba H, Krygier M, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370746
The study aimed to assess the expression of B7H3 concerning clinicopathological and histological parameters, including MSI/MSS status, CD-8 cells, tumour-infiltrating lymphocytes (TILs), budding, TNM scale and grading. Moreover, we analyzed...
9.
Ochman B, Mielcarska S, Kula A, Dawidowicz M, Robotycka J, Piecuch J, et al.
Curr Issues Mol Biol
. 2023 May;
45(4):2781-2797.
PMID: 37185706
The influence of chitinase-3-like protein 1 (YKL-40 or CHI3L1) expression on the immunological properties of the tumor microenvironment, which may affect the effectiveness of immunotherapy, is currently not sufficiently understood...
10.
Kula A, Dawidowicz M, Mielcarska S, Kiczmer P, Skiba H, Krygier M, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982953
The study aimed to investigate correlations between HHLA2 levels and parameters, including microsatellite instability (MSI) status, CD8+ cells, and histopathological features: budding, tumor-infiltrating lymphocytes (TILs), TNM scale, grading, cytokines, chemokines,...